- Home
- MRSN vs CNTB Comparison
MRSN vs CNTB Comparison
Compare MRSN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- CNTB
- Stock Information
- Founded
- MRSN 2001
- CNTB 2012
- Country
- MRSN United States
- CNTB United States
- Employees
- MRSN N/A
- CNTB N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- CNTB Health Care
- Exchange
- MRSN Nasdaq
- CNTB Nasdaq
- Market Cap
- MRSN 40.7M
- CNTB 44.2M
- IPO Year
- MRSN 2017
- CNTB 2021
- Fundamental
- Price
- MRSN $0.36
- CNTB $1.03
- Analyst Decision
- MRSN Strong Buy
- CNTB Strong Buy
- Analyst Count
- MRSN 5
- CNTB 2
- Target Price
- MRSN $5.75
- CNTB $7.50
- AVG Volume (30 Days)
- MRSN 2.3M
- CNTB 94.8K
- Earning Date
- MRSN 08-12-2025
- CNTB 05-15-2025
- Dividend Yield
- MRSN N/A
- CNTB N/A
- EPS Growth
- MRSN N/A
- CNTB N/A
- EPS
- MRSN N/A
- CNTB N/A
- Revenue
- MRSN $34,006,000.00
- CNTB $26,033,000.00
- Revenue This Year
- MRSN N/A
- CNTB N/A
- Revenue Next Year
- MRSN $1.30
- CNTB N/A
- P/E Ratio
- MRSN N/A
- CNTB N/A
- Revenue Growth
- MRSN N/A
- CNTB N/A
- 52 Week Low
- MRSN $0.26
- CNTB $0.51
- 52 Week High
- MRSN $2.83
- CNTB $1.73
- Technical
- Relative Strength Index (RSI)
- MRSN 46.82
- CNTB 67.44
- Support Level
- MRSN $0.35
- CNTB $0.75
- Resistance Level
- MRSN $0.39
- CNTB $1.12
- Average True Range (ATR)
- MRSN 0.03
- CNTB 0.07
- MACD
- MRSN -0.00
- CNTB 0.03
- Stochastic Oscillator
- MRSN 12.30
- CNTB 76.92
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.